Lataa...
Reduced Dose Ibrutinib Due to Financial Toxicity in CLL
Ibrutinib is the only approved novel agent that is available for the treatment of relapsed-refractory and treatment-naive chronic lymphocytic leukemia patients with deletion 17p or TP53 mutation in India. The cost of ibrutinib is still prohibitive for most Indian CLL patients. We report here for the...
Tallennettuna:
| Julkaisussa: | Indian J Hematol Blood Transfus |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer India
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6439022/ https://ncbi.nlm.nih.gov/pubmed/30988561 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12288-018-1011-4 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|